Product Description
Becatecarin (rebeccamaycin analogue-RA) is an anti-tumor antibiotic with inhibitory activity against both topoisomerase II and I as well as DNA intercalating properties. (Sourced from: https://ascopubs.org/doi/10.1200/jco.2008.26.15_suppl.19060)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Helsinn Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Renal Cell Carcinoma|Cholangiocarcinoma|Kidney Cancer|Colorectal Cancer|Small Cell Lung Cancer|Liver Cancer|Gallbladder Cancer|Retinoblastoma|Brain Stem Cancer|Neuroblastoma|Bile Duct Cancer|Non-Small-Cell Lung Cancer|Sarcoma|Ovarian Cancer|Primary Central Nervous System Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2012-02587 | P2 |
Terminated |
Small Cell Lung Cancer |
2008-04-01 |
|
| CDR0000066852 | P2 |
Completed |
Neuroblastoma |
2006-09-01 |
|
| NCI-2012-01851 | P2 |
Completed |
Sarcoma|Retinoblastoma|Primary Central Nervous System Lymphoma|Brain Stem Cancer|Neuroblastoma |
2006-06-01 |
|
| CWRU2299 | P2 |
Terminated |
Gallbladder Cancer|Liver Cancer|Bile Duct Cancer|Cholangiocarcinoma |
2005-04-01 |